Rite Aid lowers guidance
This article was originally published in The Tan Sheet
Executive SummaryDrug store chain revises fiscal 2005 sales and earnings guidance to reflect slowing Rx sales growth, lower third-party reimbursement rates and the growing impact of mail-order competition. The firm expects sales of approximately $17 bil. with net earnings between $122 mil. and $150 mil., a decrease from the previously forecasted $17.1 bil. to $17.3 bil. with earnings in the $121 mil. to $167 mil. range. Though Rite Aid is "disappointed" with the downward trend, the chain is addressing the issues in the near-term with a TV ad campaign, "an aggressive pharmacy customer acquisition program in key markets and an increased emphasis on prescription file buys," according to CEO Mary Sammons...
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.